Brokerages Set GRAIL, Inc. (NASDAQ:GRAL) Price Target at $67.78

Shares of GRAIL, Inc. (NASDAQ:GRAL) have earned an average recommendation of “Hold” from the eleven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $71.1111.

GRAL has been the topic of a number of research analyst reports. Wolfe Research started coverage on GRAIL in a report on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Wall Street Zen raised shares of GRAIL from a “sell” rating to a “hold” rating in a research report on Sunday. UBS Group initiated coverage on GRAIL in a research note on Wednesday. They set a “buy” rating and a $105.00 price objective for the company. TD Cowen reiterated a “buy” rating on shares of GRAIL in a research note on Wednesday, July 15th. Finally, The Goldman Sachs Group initiated coverage on GRAIL in a report on Friday, June 5th. They issued a “neutral” rating and a $60.00 price target for the company.

Insider Buying and Selling at GRAIL

In other news, CEO Joshua J. Ofman sold 5,000 shares of GRAIL stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $85.02, for a total transaction of $425,100.00. Following the completion of the sale, the chief executive officer owned 397,271 shares in the company, valued at $33,775,980.42. The trade was a 1.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Freidin sold 7,900 shares of the company’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $85.01, for a total transaction of $671,579.00. Following the sale, the chief financial officer owned 253,083 shares of the company’s stock, valued at $21,514,585.83. The trade was a 3.03% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.83% of the stock is currently owned by company insiders.

Institutional Trading of GRAIL

A number of institutional investors and hedge funds have recently modified their holdings of GRAL. Fifth Third Bancorp increased its position in shares of GRAIL by 15,733.3% in the 1st quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock valued at $25,000 after buying an additional 472 shares in the last quarter. Comerica Bank boosted its position in shares of GRAIL by 59.2% during the third quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after buying an additional 173 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in shares of GRAIL during the fourth quarter worth about $28,000. Geneos Wealth Management Inc. raised its position in GRAIL by 160.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock valued at $30,000 after buying an additional 360 shares during the last quarter. Finally, Elyxium Wealth LLC acquired a new stake in GRAIL in the 4th quarter valued at approximately $31,000.

GRAIL Price Performance

GRAIL stock opened at $76.23 on Monday. GRAIL has a fifty-two week low of $36.87 and a fifty-two week high of $118.84. The firm has a fifty day moving average price of $73.49 and a two-hundred day moving average price of $62.69. The firm has a market cap of $3.41 billion, a price-to-earnings ratio of -7.82 and a beta of 3.25.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.66) by $0.10. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%.The company had revenue of $44.69 million for the quarter, compared to the consensus estimate of $42.39 million. As a group, sell-side analysts expect that GRAIL will post -10.41 earnings per share for the current year.

GRAIL Company Profile

GRAIL, Inc is a healthcare company focused on developing blood-based tests for the early detection of cancer. Its technology uses genomic and epigenomic signals, including patterns of DNA methylation, to identify signals associated with multiple cancer types from a single blood sample.

The company’s primary product is Galleri, a prescription blood test designed to screen for signals of more than 50 types of cancer, including cancers that currently lack recommended screening methods. Galleri is intended to complement, not replace, guideline-recommended cancer screenings, and a positive result requires follow-up diagnostic testing to determine whether cancer is present and where it may be located.

GRAIL was founded in 2016 as a subsidiary of Illumina and became an independent publicly traded company following its separation from Illumina in 2021.